Intraocular Concentrations of Growth Factors and Cytokines in Retinal Vein Occlusion and the Effect of Therapy with Bevacizumab
Intraocular Concentrations of Growth Factors and Cytokines in Retinal Vein Occlusion and the Effect of Therapy with Bevacizumab
复制标题
DOI：
10.1167/iovs.08-2510
复制
发表时间：
2009-03-01
影响因子：
4.4
通讯作者：
Schmidt-Erfurth, Ursula
中科院分区：
文献类型：
--
作者：
Funk, Marion;Kriechbaum, Katharina;Schmidt-Erfurth, Ursula
目的。目的探讨视网膜中央静脉阻塞(CRVO)和分支静脉阻塞(BRVO)患者在贝伐单抗治疗前后的生长因子和炎性细胞因子的浓度变化及其与疾病活动性的关系。方法：前瞻性临床试验中，CRVO(n=5)或BRVO(n=8)患者13眼。贝伐单抗在基线、1个月和2个月时玻璃体腔内注射。如果OCT显示水肿或出现视力丧失，则在每月复诊时进行再次治疗。每次注射时都要采集房水样本。术后随访15个月。以来自白内障患者的样本作为对照。结果：在贝伐单抗治疗期间，血管内皮生长因子水平在前2个月降至低于检测水平。只要再治疗的标准被满足，血管内皮生长因子就可以再次被检测到。血管内皮生长因子的降低与视网膜中央厚度(CRT)的降低和视力(VA)的提高有关。CRVO患者房水中VEGF、IL-6、IL-8、IP-10、MCP-1和PDGF-AA水平均显著高于对照组。玻璃体内注射贝伐单抗可显著降低生理水平下的血管内皮细胞生长因子水平，并且在连续三个月重复治疗的负荷量下仍保持较低水平。黄斑水肿与房水中血管内皮生长因子水平有关。(投资眼科VS科学。2009年；50：1025-1032)doi：10.1167/iovs.08-2510
PURPOSE. To investigate concentrations of growth factors and inflammatory cytokines in eyes with central (CRVO) and branch (BRVO) retinal vein occlusion before and during therapy with bevacizumab and to identify associations with disease activity.METHODS. In a prospective clinical trial, 13 eyes of patients with CRVO (n = 5) or BRVO (n = 8) were included. Bevacizumab was administered intravitreously at baseline and months 1 and 2. Retreatments were given at monthly visits if OCT showed edema or when vision loss occurred. Aqueous humor samples were taken each time injections were performed. Follow-up was 15 months. Samples from patients with cataract served as the control. Multiplex bead assays were used for measurement of 28 growth factors and cytokines.RESULTS. During therapy with bevacizumab, VEGF levels were reduced to below detection in the first 2 months. Whenever criteria for retreatment were met, VEGF was measurable again. The decrease in VEGF was associated with a decrease in central retinal thickness (CRT) and improvement in visual acuity (VA). Significantly increased concentrations of VEGF, IL-6, IL-8, IP-10, MCP-1, and PDGF-AA were observed in aqueous humor samples of patients with CRVO compared with the control samples.CONCLUSIONS. VEGF levels were significantly elevated in patients with CRVO compared with control subjects. Intravitreal injections of bevacizumab resulted in a substantial decrease of VEGF under physiologic levels and remained low under the loading dose of three consecutive monthly retreatments. Macular edema was related to VEGF levels in the aqueous humor. (Invest Ophthalmol Vis Sci. 2009; 50: 1025-1032) DOI: 10.1167/iovs.08-2510